not receptor modulator 1

NOT Receptor Modulator 1 (2-(3-(2-(4-chlorophenyl)imidazo[1,2-a]pyridin-6-yl)phenyl)propan-2-ol) 是核受体 NOT 调节剂。

Opioid receptor modulator 1 is a modulator of opioid receptor.

GLP-1 Receptormodulator 1 (Compound 7) 作为一种高效的GLP-1 receptor正变构调节剂，主要应用于肥胖症及2型糖尿病的相关研究。

α5-GABAA receptor modulator 1 (Compound A-4) 是一种针对 a5 亚基的GABAA受体沉默变构调节剂 (SAM)，适用于中枢神经系统 (CNS) 疾病的研究。

D3 5-HT receptor modulator-1 (compound 5i) 是一种具有选择性抑制多巴胺D3受体和5-HT2A受体的拮抗剂，同时也是部分激动5-HT1A受体的化合物。该化合物对多巴胺D3、5-HT2A和5-HT1A受体的Ki值分别为4.5 nM、11.9 nM和15.3 nM。相比之下，它对多巴胺D2受体、5-HT2C受体和hERG通道的亲和力较低，具有非典型抗精神病特性。

GluN2B receptor modulator-1 is a potent and selective allosteric modulator of the GluN2B receptor. It demonstrates negative modulation, inhibiting receptor activity, and exhibits high selectivity towards the GluN2B subunit, with an impressive IC50 value of 31 nM.

σ1 Receptor μ Opioid receptor modulator 1 (Compound 44) 是一种有效的σ1受体拮抗剂（Ki= 1.86 nM）和μ阿片受体激动剂（Ki=2.1 nM）。σ1 Receptor μ Opioid receptor modulator 1 具体有效的镇痛活性，可用于神经性疼痛的研究。

GPR52受体调制剂1（程序1）是一种有潜力用于神经精神疾病研究的GPR52受体调节剂。

Orexin receptormodulator-1 是一款针对食欲素受体的调节剂，主要应用于物质成瘾、惊恐障碍、焦虑、创伤后应激障碍 (PTSD)、疼痛、抑郁、季节性情感障碍、进食障碍及高血压的科研领域。

Adenosine receptor modulator 1 作为一种胶原蛋白 VII (C7) 诱导剂，在供体来源的角质形成细胞中可上调 COL7A1 mRNA 表达。此外，该化合物还可与Gentamicin协同作用，共同提升总 C7 水平。

SR 1903 is a modulator of retinoic acid receptor-related orphan receptor γ (RORγ) and liver X receptor (LXR).1 It is an inverse agonist of RORγ (IC50 = ~100 nM in a cell-based reporter assay) and an agonist of LXR. It also binds to peroxisome proliferator-activated receptor γ (PPARγ; IC50 = 209 nM) but does not activate it. SR 1903 (10 μM) inhibits LPS-induced expression of triggering receptor expressed on myeloid cells 1 (TREM-1) in RAW 264.7 cells. It also inhibits LPS-induced expression of the LXR target genes IL-6 and IL-33 and increases expression of ABCG1, FASN, and SCD-1 in RAW 264.7 cells. SR 1903 (20 mg kg twice per day) reduces severity score in a mouse model of collagen-induced arthritis. It reduces blood glucose levels in a glucose tolerance test, serum levels of total cholesterol and LDL, body weight, and fat mass in a mouse model of high-fat diet-induced obesity.References1. Chang, M.R., Ciesla, A., Strutzenberg, T.S., et al. Unique polypharmacology nuclear receptor modulator blocks inflammatory signaling pathways. ACS Chem. Biol. 14(5), 1051-1062 (2019). SR 1903 is a modulator of retinoic acid receptor-related orphan receptor γ (RORγ) and liver X receptor (LXR).1 It is an inverse agonist of RORγ (IC50 = ~100 nM in a cell-based reporter assay) and an agonist of LXR. It also binds to peroxisome proliferator-activated receptor γ (PPARγ; IC50 = 209 nM) but does not activate it. SR 1903 (10 μM) inhibits LPS-induced expression of triggering receptor expressed on myeloid cells 1 (TREM-1) in RAW 264.7 cells. It also inhibits LPS-induced expression of the LXR target genes IL-6 and IL-33 and increases expression of ABCG1, FASN, and SCD-1 in RAW 264.7 cells. SR 1903 (20 mg kg twice per day) reduces severity score in a mouse model of collagen-induced arthritis. It reduces blood glucose levels in a glucose tolerance test, serum levels of total cholesterol and LDL, body weight, and fat mass in a mouse model of high-fat diet-induced obesity. References1. Chang, M.R., Ciesla, A., Strutzenberg, T.S., et al. Unique polypharmacology nuclear receptor modulator blocks inflammatory signaling pathways. ACS Chem. Biol. 14(5), 1051-1062 (2019).

GAT229 is a positive allosteric modulator of cannabinoid receptor 1 (CB1) and the S-(-) enantiomer of the CB1 modulator GAT211. It does not activate the receptor on its own but enhances the binding and activity of CB agonists. GAT229 (1 μM) enhances the binding of the CB1 full agonist CP 55,940 to CHO cells expressing human recombinant CB1 (hCB1), as well as the activity of 2-arachidonoyl glycerol , arachidonoyl ethanolamide , and CP 55,940 in arrestin2 recruitment assays and increases ERK1 2 and PLCβ3 phosphorylation in HEK293 cells expressing hCB1. GAT229 (1 μM) enhances depolarization-induced suppression of excitation but does not inhibit excitatory postsynaptic currents (EPSCs) in murine autaptic hippocampal neurons. GAT229 (0.2%, topical) reduces intraocular pressure by 5.8 and 7.7 mm Hg after 6 and 12 hours, respectively, in a transgenic mouse model of ocular hypertension using nose, ear, eye mutation (nee) mice.

SR-1903 is a modulator of retinoic acid receptor-related orphan receptor γ (RORγ) and liver X receptor (LXR). It is an inverse agonist of RORγ and an agonist of LXR. It also binds to peroxisome proliferator-activated receptor γ (PPAR) but does not activate it. SR-1903 inhibits LPS-induced expression of triggering receptor expressed on myeloid cells 1 (TREM-1). It also inhibits LPS-induced expression of the LXR target genes IL-6 and IL-33 and increases expression of ABCG1, FASN, and SCD-1. SR-1903 reduces the severity of collagen-induced arthritis. It reduces blood glucose levels in a glucose tolerance test, serum levels of total cholesterol and LDL, body weight, and fat mass in a mouse model of high-fat diet-induced obesity.